PFS
LGND icon

Prospera Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Prospera Financial Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-64
Closed -$4K – 2177
2022
Q1 		$4K Buy
+64
New +$4.64K ﹤0.01% 2326

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Prospera Financial Services's LGND Position: Q2 2022 in Review

Prospera Financial Services sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 64 shares — an estimated $4K sold.

Prospera Financial Services first reported a position in LGND in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

  • Prospera Financial Services reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 64 Ligand Pharmaceuticals shares in Q2 2022, an estimated $4K.
  • Prospera Financial Services first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Ligand Pharmaceuticals position peaked at $4K in Q1 2022.
  • 197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.